Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: GlobeNewswire
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic candidates for the treatment of gonorrhoea in a late-breaking presentation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (‘ECCMID 2018’) in Madrid, Spain. Gonorrhoea is an area of high unmet medical need with only one treatment option recommended by the US Centres for Disease Control. It has also been identified as a priority pathogen by the World Health Organisation, cited on a list of bacteria deemed to pose the greatest risk to human health. The pressing need for novel, effective antibiotics for gonorrhoea is driving Summit’s discovery and development efforts around a series of new mechanism antibiotics as potential front-line treatments for this infection. In the data presented, the series was shown to have a number of key characteristics that
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $7.00 price target on the stock.MarketBeat
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024Business Wire
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024Business Wire
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsBusiness Wire
SMMT
Earnings
- 5/1/24 - In-Line
SMMT
Sec Filings
- 5/1/24 - Form S-8
- 5/1/24 - Form 8-K
- 5/1/24 - Form 10-Q
- SMMT's page on the SEC website